Dr. Robert M. Westcott, M.D.
Family Medicine (Family Medicine Physician)
409 S Main St
Lindsay, OK 73052
Who else practices at this address →
Garvin County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Oklahoma College of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 85
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of Oklahoma College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
OK license 18951
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Norman Regional Norman, OK
- Lindsay Municipal Hospital Lindsay, OK
Medical groups
- Lindsay Medical Plaza LLC (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 85
- Services billed
- 764
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 231 | 81 |
| Established patient office or other outpatient visit, 20-29 minutes | 82 | 47 |
| Insertion of needle into vein for collection of blood sample | 81 | 43 |
| Testing for presence of drug, read by direct observation | 69 | 15 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 35 | 35 |
| Hemoglobin a1c level | 32 | 27 |
| Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | 23 | 23 |
| Administration of influenza virus vaccine | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Buprenorphine-Naloxone (buprenorphine hcl/naloxone hcl) Other prescribers in Lindsay, OK | 310 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Lindsay, OK | 108 |
| Levothyroxine Sodium Other prescribers in Lindsay, OK | 107 |
| Gabapentin Other prescribers in Lindsay, OK | 80 |
| Lisinopril Other prescribers in Lindsay, OK | 64 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Lindsay, OK | 59 |
| Amitriptyline Hcl Other prescribers in Lindsay, OK | 57 |
| Escitalopram Oxalate Other prescribers in Lindsay, OK | 56 |
| Amlodipine Besylate Other prescribers in Lindsay, OK | 53 |
| Atorvastatin Calcium Other prescribers in Lindsay, OK | 51 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $39.22 in total to this clinician.
| Novo Nordisk Inc | $21.31 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $17.91 |
| Food and Beverage | $39.22 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $352,495 in research payments for these studies, mostly to the institutions running them.
- Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder
Indivior Inc. · Completed · NCT06384157 - A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK)
E.r. Squibb & Sons, L.l.c. - Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
E.r. Squibb & Sons, L.l.c. · Completed · NCT04036435
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.